º£½ÇÉçÇø

Application Deadline: April 30, 2025

Budget: Up to $300,000

Award: AbbVie seeks proposals to enhance the adoption of guideline-recommended care for AML patients over 65 who are ineligible for intensive chemotherapy, particularly in community settings. While treatment improves outcomes, over 50% of these patients receive no therapy. Those treated at academic centers fare better due to greater expertise and resources. Partnerships between community and academic centers are key to optimizing care. AbbVie is interested in co-management models that improve AML patient outcomes through collaboration between academic institutions, community practices, and oncology leaders. Proposals should demonstrate measurable impact, scalability, and the potential for broader application.

Please contact Mary Nunciato, Senior Director of Foundation Relations, at mary.hall@bcm.edu for additional information.

The Dan L Duncan Comprehensive Cancer Center is releasing the first round of Bench to Preclinical Validation (BTPV) RFA for Spring 2025, to be awarded no later than July 2025. The deadline for the BTPV is May 1, 2025.

How to Apply

Please refer to the for detailed information.

Upload all the application requirements as a single PDF file to the DLDCCC Proposal Submission Portal by May 1, 2025.

For questions about this RFA, please contact DLDCCCgrants@bcm.edu. Thank you.

The Pew-Stewart Scholars for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The award provides $300,000 in flexible support—$75,000 per year for a four-year period. Dan L Duncan Comprehensive Cancer Center is invited to submit one nominee for this award.

In line with The Alexander and Margaret Stewart Trust’s mission to invest in innovative, cutting-edge cancer research that may accelerate and advance progress toward a cure for cancer, applications are invited from nominees conducting cancer research. This program is distinct from the Pew Scholars Program, and it follows a different, but parallel set of guidelines and procedures for nominating an applicant whose research is related to cancer.

This program does not fund clinical trials research. Strong proposals will incorporate particularly creative and pioneering approaches to basic, translational, and applied cancer research. Candidates whose work is based on biomedical principles but who bring in concepts and theories from more diverse fields are encouraged to apply.

Ideas with the potential to produce an unusually high impact are encouraged. Selection of the successful candidates will be based on a detailed description of the work that the applicant proposes to undertake, evaluations of the candidate’s performance, and notable past accomplishments, including honors, awards, and publications. In evaluating the candidates, the National Advisory Committee gives considerable weight to both the project proposal and the researcher, including evidence that the candidate is a successful independent investigator and has the skill set needed to carry out their high-impact proposal.

For more detail :

Funding : Up to $75,000 per year for a four-year period, totaling to $300,000.

Key Dates: Applicants will submit an initial internal application. A candidate will be selected as a nominee to submit a full proposal to the sponsor following the dates below.

• Cancer Center Internal application due: May 4, 2025
• Institutional nomination due: May 14, 2025
• Full application due: August 27, 2025

If you are interested, please upload your current NIH biosketch and a one-page LOI including specific aims and research strategy as a single PDF file via by Sunday, May 4, 2025. This will be reviewed by the DLDCCC-appointed panel.

Format Requirement: Please name your pdf file as follows:
NAME OF SPONSOR_PI LAST NAME_LOI
Example: CPRIT_SMITH_LOI
Questions may be directed to DLDCCCgrants@bcm.edu. Thank you.

Application Deadline: May 5, 2025, by 3 p.m. ET

Budget: Up to $1 million in direct costs over two years.

Award: This award is aimed at supporting innovative, high-risk research on metastatic, lethal prostate cancer. These awards fund large-scale projects for two years. Eligible teams must consist of at least three investigators, including one young investigator, from nonprofit academic institutions.

Funding covers direct research costs and travel but excludes clinical trial direct costs, though correlative research for clinical trials is encouraged. Research proposals should focus on areas such as theranostics, novel drug targets, precision medicine, immunotherapies, AI/machine learning and tumor metabolism.

Diversity in patient studies and statistical rigor are required. Applicants from underrepresented groups and those with Veterans Administration (VA) involvement are strongly encouraged.

Please contact Mary Nunciato, Senior Director of Foundation Relations, at mary.hall@bcm.edu for additional information. 

LOI Deadline: May 5, 2025, 5 p.m. E.T.

Budget:  $250,000 per year for three (3) years, totaling $750,000; Indirect costs are not to exceed 10% of direct costs and are included in the total.

Award: The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

Please contact Andrea Calo, Assistant Vice President Foundation Relations and Strategic Partnership, at macalo@bcm.edu for additional information. 

LOI Deadline: May 19, 2025
Full Proposal Deadline: July 9, 2025
Budget: $5-$10 Million over 3-5 years inclusive of 10% indirect costs.

Award: The PCF TACTICAL Awards support large-scale, multi-institutional research projects focused on metastatic, lethal prostate cancer over a period of 3 to 5 years. While clinical trial costs are not permitted, correlative research that complements high-impact clinical trials is encouraged, with IRB submission—and preferably approval—required at the time of application. Eligible teams must consist of at least five investigators from a minimum of four non-profit academic research institutions, including two young investigators who are within six years of completing their degree or training and have received less than $2 million in direct research funding. Teams that are diverse, cross-disciplinary, and include a young investigator in senior leadership will be favored. Investigators from for-profit or government institutions are not eligible. Research proposals are sought in areas such as theranostics, targeting undruggable oncology pathways, advanced biotechnologies for precision medicine, novel immunotherapies, artificial intelligence and machine learning to improve patient outcomes, and studies on the microbiome and tumor metabolism.

Please contact Mary Nunciato, Senior Director of Foundation Relations, at mary.hall@bcm.edu for additional information.

LOI Deadline: May 23, 2025, at 1 p.m. ET
Application Deadline: August 11, 2025, at 1 p.m. ET
Budget: Up to $200,000 per year (combined direct and indirect costs) for up to two years ($400,000).

Award: This award is a joint effort to support innovative research focused on metastatic invasive lobular carcinoma (mILC) that will unlock new knowledge about lobular breast cancer, advance patient care and/or improve patient outcomes of those impacted by mILC.

Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations for additional information.

LOI Deadline: May 30, 2025

Budget: Up to a total budget of $1.5M - $2M over a period of up to 3 years, indirect costs may not exceed a maximum of 10% of direct costs.

Award: Through the CAI, the Lustgarten Foundation will provide academic, clinical researchers the opportunity to propose science-driven concepts seeking to advance the development of new therapies for pancreatic cancer patients while furthering our understanding of disease biology.

The CAI is meant to support trials concepts that are:

• Innovative and highly collaborative.
• Based on strong pre-clinical and/or clinical scientific rationale.
• Utilizing deep, translational analyses to demonstrate on-target drug mechanism(s) of action and hypotheses around disease biology.
• Advancing the development of novel therapies for pancreatic cancer patients with plans for continuation, if successful

Please contact Lyndsie Whitehead, Assistant Director Foundation Relations, at lyndsie.whitehead@bcm.edu for additional information.

Application Deadline: June 1, 2025

Budget:

Stage One: $135,000 per year for two years direct costs, plus 10% allowable indirect costs ($297,000 allowable total costs).

Stage Two: Up to $545,000 direct costs for up to18 months, plus 10% allowable indirect costs.

Award: Mission Boost Grants (MBG) are designed to support research projects that specifically focus on translation to human testing. MBGs are opportunities for independent investigators at all levels to apply for additional, or "boost," resources for innovative, clinical-enabling projects.

MBGs offer 2 stages of funding:

1. Stage One: Requires the investigator to develop outcome-specific, unequivocal milestones that reduce the risks of studying a new drug, device, or procedure in patients.  
2. Stage Two: Supports testing in cancer patients.

Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations, at lyndsie.whitehead@bcm.edu for additional information.

Deadline: June 1, 2025

Budget: Up to $215,000 per year (direct costs), plus 10% allowable indirect costs, with a project period up to four years.

Award: Research Scholar Grants (RSG) provide support for independent, self-directed researchers.  Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) priority research area listed below.

• Etiology (causes of cancer)
• Obesity/Healthy Eating and Active Living (HEAL)
• Screening and Diagnosis
• Treatment
• Survivorship
• Health Equity Across the Cancer Continuum

Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations, at lyndsie.whitehead@bcm.edu for additional information.

Application Deadline: June 1, 2025

Budget: $100,000 

Award: Funds translational, clinical, basic and delivery projects that further efforts in pediatric brain cancer. Focus is on diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG) and Medulloblastoma.

Please contact Alex Hood, Associate Director Foundation Relations at alex.hood@bcm.edu with any questions.

Application Deadline: June 13, 2025

Budget: $150,000 over 1 year

Award: To provide seed funding to support the K award resubmission efforts of strong pediatric cancer-focused grant applications that narrowly missed the pay line at the NIH. Ideal candidates are those with NIH K award applications (e.g., K08, K23) that were scored. The application period will open on a rolling basis.

Please contact Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu with any questions.

Application Deadline: July 1, 2025, at 4 p.m. C.T.

Budget: $50,000 (direct costs) over 1- or 2-years

Award: Awards to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the National Clinical Trials Network (NCTN). These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early-stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Direct application to future SWOG research, larger in scope, is critical and will be a metric of success for this funding program. Another metric of success will be the ability to obtain extramural funding based on studies done during the tenure of the support of this grant. Any SWOG member investigator eligible for NIH funding is encouraged to submit to this program.

Please contact Alex Hood, Associate Director Foundation Relations, at alex.hood@bcm.edu for additional information.

Application Deadline: Ongoing until funds are used.

Budget: $20,000-$40,000, for one year.

Award: The Colon Cancer Coalition seeks to provide funds, to liked-minded partners advancing colon cancer research. Funds must be used on programs that will benefit individuals in and around the event city where the money is raised. Priority will be given to programs working to increase screening for adults over 50 to reach the national goal of 80%, patient screening navigation, or addressing young adult onset colorectal cancer.

Contact: Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations at lyndsie.whitehead@bcm.edu for additional information.

Application Deadline: Funding is available on a rolling basis and new grants are awarded frequently.
Budget: $50,000 ~ $828,027, from 6 months to 36 months (average $224,000 for 2 years). NTAP supports indirect costs at a maximum of 10% of direct costs.  

Award: The Johns Hopkins University School of Medicine - Neurofibromatosis Therapeutic Acceleration Program (NTAP) supports research projects designed to accelerate development of effective treatments for NF1 associated peripheral nerve sheath tumors.  NTAP’s is open to any stage of drug development.  However, proposal must focus on the peripheral nerve tumors of NF1 (Cutaneous, Plexiform and Atypical).

Please contact Lyndsie Whitehead, Assistant Director of Foundation Relations for additional information.